source
- Moderna’s stock soars after Phase 3 success of melanoma vaccine with MerckBioPharma Dive’s latest data-visualization series charts Moderna’s dramatic stock rebound in 2026 after a period of decline. The company had struggled when demand for its COVID-19 vaccine fell, pr…
- City Therapeutics raises $200 million in IPO, becoming 26th biotech listing of 2026City Therapeutics announced that it has completed a $200 million initial public offering, making it the 26th biotech to go public in 2026. The company, based in Kendall Square, will begin trading…